Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine
dc.contributor.author | Sisson, James C. | en_US |
dc.contributor.author | Hutchinson, Raymond J. | en_US |
dc.contributor.author | Normolle, Daniel P. | en_US |
dc.contributor.author | Shapiro, Brahm | en_US |
dc.contributor.author | Carey, James E. | en_US |
dc.contributor.author | Zasadny, Kenneth R. | en_US |
dc.contributor.author | Zempel, Shirley A. | en_US |
dc.date.accessioned | 2006-09-11T18:15:41Z | |
dc.date.available | 2006-09-11T18:15:41Z | |
dc.date.issued | 1994-01 | en_US |
dc.identifier.citation | Sisson, James C.; Shapiro, Brahm; Hutchinson, Raymond J.; Carey, James E.; Zasadny, Kenneth R.; Zempel, Shirley A.; Normolle, Daniel P.; (1994). "Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine." European Journal of Nuclear Medicine 21(1): 46-52. <http://hdl.handle.net/2027.42/46835> | en_US |
dc.identifier.issn | 0340-6997 | en_US |
dc.identifier.issn | 1619-7089 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/46835 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8088285&dopt=citation | en_US |
dc.description.abstract | We searched for methods that would enable prescriptions of the maximum tolerable doses of iodine-131 metaiodobenzylguanidine (MIBG) and iodine-125 MIBG in the treatment of patients with neuroblastoma. We correlated doses, defined in different ways, with subsequent platelet levels in treated patients to determine accurate predictors of the most frequent toxicity, thrombocytopenia. Nine patients with neuroblastoma were given 131 I-MIBG (4.9–8.1 GBq or 132–220 mCi) and ten were given 125 I-MIBG (8.3-30.0 GBq or 224–809 mCi) as initial treatments. These therapies were sufficiently varied that correlations could be made between indices of the doses and the subsequent toxicity as reflected in circulating platelet levels. Predictors of toxicity were: whole-body absorbed dose of radiation (cGy) calculated from pretherapy tracer doses of 131 I-MIBG; GBq/kg of body weight; and GBq/m 2 of body surface area. Toxicity was recorded as the nadir of the platelet level and platelet/pretherapeutic level (platelet ratio). For treatments with 131 I-MIBG, the highest correlation was obtained between cGy and the logo 10 -transformed platelet ratio ( r =−0.86), but comparison of GBq/m2 and the platelet nadir ( r =−0.76) or the platelet ratio ( r =−0.74) or the log 10 − transformed platelet ratio ( r =−0.73) gave comparable and statistically significant results. For treatments with 125 I-MIBG, significant correlations were obtained between GBq/m 2 and the platelet ratio ( r =−0.81) or GBq/kg and the log 10 − -transformed platelet ratio; the correlation between cGy and any toxicity index was low. Per administered GBq, 131 I-MIBG was 2.6 times more potent than 125 I-MIBG in causing a platelet ratio of 0.1. Thus, in predicting toxicity, therapeutic doses of 131 I-MIBG expressed as GBq/m 2 performed satisfactorily and almost as well as whole-body cGy, and treatment doses of 125 I-MIBG expressed as GBq/m 2 or GBq/kg performed satisfactorily and much better than whole-body cGy. | en_US |
dc.format.extent | 737600 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Thrombocytopenia | en_US |
dc.subject.other | Dosimetry | en_US |
dc.subject.other | Imaging / Radiology | en_US |
dc.subject.other | Metaiodobenzylguanidine | en_US |
dc.subject.other | Toxicity | en_US |
dc.subject.other | Therapy | en_US |
dc.subject.other | Nuclear Medicine | en_US |
dc.title | Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Physics | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Nuclear Medicine, University of Michigan Medical Center, 1500 E. Medical Center Drive, 48109-0028, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Nuclear Medicine, University of Michigan Medical Center, 1500 E. Medical Center Drive, 48109-0028, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Biostatistics, School of Public Health, University of Michigan Medical Center, 1500 E. Medical Center Drive, 48109-0028, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Pediatrics, Division of Hematology and Oncology, University of Michigan Medical Center, 1500 E. Medical Center Drive, 48109-0028, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Nuclear Medicine, University of Michigan Medical Center, 1500 E. Medical Center Drive, 48109-0028, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Nuclear Medicine, University of Michigan Medical Center, 1500 E. Medical Center Drive, 48109-0028, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Nuclear Medicine, University of Michigan Medical Center, 1500 E. Medical Center Drive, 48109-0028, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 8088285 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/46835/1/259_2004_Article_BF00182305.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00182305 | en_US |
dc.identifier.source | European Journal of Nuclear Medicine | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.